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Spasticite´ (I) / Revue d’E´pide´miologie et dedrive) at least in part. We define this stretch-sensitive, misdirected descending
command as spastic cocontraction. While spastic cocontraction is really the
main antagonistic mechanism impeding movement, in particular leg
movements during gait, muscle overactivity is often assumed to be represented
by mere measurements of resistance to passive movement. A five-step clinical
assessment, including a quantitative assessment of active range of motion, may
better serve the clinician to reflect the amount of cocontraction.
Another critical phenomenon is stretch-sensitive paresis, which is the aggravation
of paresis of agonist command by the stretched position of the antagonist. The
physiological underpinnings of spastic cocontraction and stretch-sensitive paresis
probably involve neuronal rarefaction in agonist command, hypo-excitabilty of
the remaining upper motor neurons, hyperexcitability of the lower motor neurons
subserving the more shortened muscles and reduction or reversal into facilitation
of Ia and groups II reciprocal inhibition.
Considering its determinants (agonist effort and muscle position), treatment of
spastic cocontraction and stretch-sensitive paresis – and management of
deforming spastic paresis in general – should logically involve a combination of:
– prolonged stretching postures for the more overactive and shortened
antagonists, potentially in association with focal weakening agents such as
botulinum toxin;
– intensive motor training (e.g. non assisted maximal amplitude rapid
alternating movements and task-related exercises) of the less overactive
muscles.
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Botulinum toxin is now the reference treatment in focal spasticity, however, in
the context of multiple sclerosis few studies have been conducted. The objective
of this work is to try to clarify the use of botulinum toxin in multiple sclerosis,
particularly in terms of indications.
Method.– We analyzed retrospectively all cases of patients with multiple
sclerosis who received botulinum toxin injection on the pole Saint-Hélier
between 2007 and 2010.
Results.– During these 4 years, 673 patients including 126 people with MS have
benefited from treatment with botulinum toxin. The population consists of 85
women and 41 men, mean age 49.4  11 years with an average EDSS score of
5.8  1.7 (2.5 to 9.5).
The most common indications are abnormal gait and difficulties in nursing.
The lower limbs are usually involved, only 11 patients have benefited injection
in the upper limbs. A specific indication was the vesico-sphincter dyssynergia
with nine people.
From the given files, different clinical situations can be described. The most
common indication is to improve walking, in this situation the triceps surae is
most often injected, in patients with a mean age 48.5  /11 years with an
average EDSS of 5  1.
For higher EDSS, the objective is to improve nursing care, positioning, in this
case, the most frequently injected muscles are adductors and hamstrings, our
population in this context has a mean EDSS of 7.7  1, with an average age of
52.4  11 years.
Patient satisfaction is generally high.
Discussion and conclusion.– The objective of this work was to have an overview
of the use of botulinum toxin in spasticity management in multiple sclerosis.
Two main indications have emerged: the gait disorders associated with
spasticity of the triceps surae and the difficulties of nursing, related to the
spasticity of the adductors.
http://dx.doi.org/10.1016/j.rehab.2012.07.824CO20-003-e
Interest and tolerance of botulinum toxin for the treatment
of spasticity in patients with lateral amyotrophic sclerosis
S. Deffontaines Rufin *, S. Pol, K. Vassilev, M. Wiese, D. Mazevet
Service de MPR, hoˆpital Pitie´-Salpeˆtrie`re, consultation spasticite´,
47-83, boulevard de l’Hoˆpital, 75013 Paris, France
*Corresponding author.
E-mail address: stephanie.deffontaines@psl.aphp.fr.
Keywords: Lateral amyotrophic sclerosis; Spasticity; Botulinum toxin
Introduction.– Spasticity is a frequent and handicapping symptom in patients
with LAS [1]. Before the use of botulinum toxin, the only treatment associated
physiotherapy and oral medication.
Methods.– Forty-five patients suffering from LAS with either paraparesia
(n = 10) or tetraparesia (n = 25) were referred to the specialized consultation in
Physical Rehabilitation Medicine department in order to treat their spasticity.
Some patients walked independently (n = 4), some required human or technical
help for deambulation (n = 38), some were unable to walk (n = 3). Their
medical charts were retrospectively analyzed, to determine the efficacy,
tolerance and side-effects of botulinum toxin therapy.
Results.– Thirty-nine patients received botulinum toxin injections in their
inferior members, in order to ameliorate ambulation (n = 36), sitting or nursing
(n = 3). In 16 patients, a motor bloc of rectus femoris muscle was made. Five
patients out of them were considered as ineligible for botulinum toxin therapy.
Twenty-one patients were satisfied with the treatment that was continued.
Eighteen patients stopped botulinum toxin therapy after the first injection either
because of lack of improvement either by diseased progression. One patient
experienced a transient respiratory degradation after treatment.
Discussion and conclusion.– Botulinum toxin therapy provided clinical
amelioration of spasticity in more than a half of our patients. One patient
had a transient respiratory degradation. To our knowledge, no study has been
reported about the efficacy and tolerance of toxin therapy in spasticity
management of LAS patients. This treatment is used to treat hypersialorrhea,
without severe side effect [2]. Nevertheless, the treatment should be started with
low doses. As LAS patients often suffer from severe motor loss, motor bloc of
the nerve of rectus femoris muscle should be perform before of botulinum toxin
injections in this muscle.
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Introduction.– Botulinum toxin is the first-line therapy in the management of
focal spasticity.
Through this work we want to evaluate our modest experience with the use of
this therapeutic method.
Materials and methods.– Fifty-two patients with focused spasticity due to
various pathologies were treated with botulinum toxin in the year 2011.
A pre therapeutic assessment and three weeks after injection of predetermined
muscles was performed taking into account the following parameters:
– the pain intensity assessed by visual analog scale;
– spasticity measured by Ashworth scale;
– the range of motion measured by goniometry;
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